Tradestie Institutional Equity Comparison Engine
CGEN vs NVCT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGEN Overall Edge
CGEN Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin while NVCT counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CGEN trades at 12.4x Forward P/E with 41.3% operating margin (+102.1% YoY revenue) versus NVCT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro) against NVCT sits in BREAKDOWN (22nd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CGEN
CGEN 12.4x vs NVCT N/M Fwd P/E
Growth & Margin Winner
CGEN
Op Margin 41.3% vs 0.0% ยท YoY +102.1% vs +0.0%
Momentum & Technical Winner
NVCT
1Y +23.2% vs +218.9% ยท 52W Pos 33% vs 57%
Options & Structure Winner
NVCT
BREAKDOWN (57th %ile IV) vs BREAKDOWN (22nd %ile IV)
CGEN
NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap
$193.2M
1M Return
+2.54%
1Y Return
+23.17%
Forward P/E
12.4x
Unified AI Score
47.1 / 100
HOLD
Tech 44.0
Fund 52.0
Flow 54.0
Mom 64.0
NVCT
NASDAQ
Nuvectis Pharma, Inc. Common Stock
Pharmaceutical Preparations
$19.20
+0.47% 1D
Market Cap
$657.2M
1M Return
+1.37%
1Y Return
+218.94%
Forward P/E
N/M
Unified AI Score
53.4 / 100
HOLD
Tech 58.0
Fund 59.0
Flow 66.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CGEN +23.17%
NVCT +218.94%
Spread: +195.77 pp (NVCT Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CGEN TTM Op. Margin: 41.3%
NVCT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CGEN vs NVCT. Trailing 12-month operating profitability (CGEN 41.3% vs NVCT 0.0%) and valuation multiples (CGEN 12.4x vs NVCT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CGEN | NVCT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $193.2M | $657.2M | Larger Scale | NVCT |
| Trailing P/E Ratio Valuation | 5.2x | N/M | Lower Multiple | CGEN |
| Forward P/E Ratio Valuation | 12.4x | N/M | Lower Multiple | CGEN |
| Revenue Growth (YoY) Growth | +102.1% | +0.0% | Higher Growth | CGEN |
| Operating Margin (TTM) Profitability | 41.3% | 0.0% | Higher Margin | CGEN |
| Net Profit Margin Profitability | 47.9% | 0.0% | Higher Margin | CGEN |
| Return on Equity (ROE) Capital Efficiency | 57.2% | -67.0% | Higher ROE | CGEN |
| 52-Week Range Position Momentum | 33% ($1โ$3) | 57% ($6โ$29) | Stronger Trend | NVCT |
| Beta / 30D Volatility Risk Regime | 1.44ฮฒ ยท 62% Vol | 0.70ฮฒ ยท 82% Vol | Lower Realized Risk | CGEN |
| Unified Institutional Score Composite Signal | 47.1 / 100 (HOLD) | 53.4 / 100 (HOLD) | Higher Composite | NVCT |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CGEN vs NVCT Buy Guide
CGEN
BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
57th %ile
IV Regime
Balanced (25thโ60th %ile)
NVCT
BREAKDOWN
99d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
22nd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CGEN nor NVCT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.